BioNeuronics

BioNeuronics is a clinical-stage biotechnology company focused on developing regenerative gene therapies for neurodegenerative disorders, particularly Alzheimer's disease and Amyotrophic Lateral Sclerosis (ALS). The company utilizes adeno-associated virus (AAV) vectors to deliver neurotrophic factors, such as Brain-Derived Neurotrophic Factor (BDNF), directly to the central nervous system to promote neuronal survival and synaptic plasticity. This approach aims to slow or reverse disease progression by addressing the underlying loss of trophic support in the aging or diseased brain. Founded by Dr. Mark Tuszynski of UC San Diego, BioNeuronics translates decades of research into potential disease-modifying treatments. The company's lead candidate is currently in Phase 1 clinical testing for early-stage Alzheimer's disease.